Robert Mijumbi,
C/O Ssenkaaba & Co. Advocates,
Plot 245 Jinja Road,
2nd Floor Suite 2F2/3 MK House, Bweyogerere,
P.O. Box 6487, Kampala.
Email: miberto@hotmail.co.uk
Mobile: +256 715 332 824

13th August 2021

The Executive Secretary,
National Drug Authority,
Rumee Towers, Plot 19 Lumumba Avenue,
P.O. Box 23096, Kampala.

Dear Scientist,

REQUEST FOR PERMISSION TO CONDUCT PHASE I CLINICAL TRIAL OF MY COVID-19 CURE CANDIDATE (BertoCOV)

As you must have known through my previous letters to you, I have been conducting investigations to develop therapeutics for **HIV**, **Hepatitis B**, **Cancer** and **Covid-19**. Basing on my laboratory results, the Covid-19 cure candidate is ripe for phase I clinical trial and I request that the National Drug Authority give me clearance to do so, starting with the oral regimen. Attached to this letter is a profile of Covid-19 cure candidate, and for ease of future reference, those of HIV, Hepatitis B and Cancer are also attached. Also, a one (1) gram sample of each of the candidates is attached and marked as follows; HIV (A), Hepatitis B (B), Cancer (C), and Covid-19 (D).

Sincerely,

Robert Mijumbi
C.E.O. Biobert Research Group Ltd.

CC: H.E. Gen. Yoweri Kaguta Tibuhaburwa Museveni, President of the Republic of Uganda
The Rt. Hon. Speaker, Parliament of the Republic of Uganda
The Rt. Hon. Prime Minister
The Director Research, Ministry of Science, Technology and Innovation
The Permanent Secretary, Ministry of Health
The Executive Secretary, Uganda National Council for Science and Technology
The Pharmaceutical Society of Uganda
The Uganda Medical Association
The Uganda Medical and Dental Practitioners Council
The Uganda Cancer Institute
The Uganda Aids Commission
The Inspector General of Police

Received by
13/08/2021

13.08.21
Lumumba H
0774197937

Received on behalf of UMA

Received
13/08/2021

NATIONAL DRUG AUTHORITY REGISTRY	
Date Received	13/8/21
Time:	1235 PM
Registry No.	5405/21
Received by:	Patrick
Dept.	SA

PROFILE OF COVID-19 CURE CANDIDATE

Physicochemical Characteristics		
Dark Field Micrograph	Brand Name	BertoCOV
 X100	Nature of API	Polypeptide
	Minimum Anticipated Biological Effect Level	660 mg
	Infrared Spectroscopy	See pages 9 & 10
	Composition of Processed Drug (%)	• API 13.44% • Excipients 86.56%
	Kinase Activity	None
	Stability	Biological function lost beyond 43ºC
	Dissolution	100%
	Bioavailability	100%
	Dosage Form	Powder
	Route of Administration	Oral

Pharmacokinetics

The whole powder is dissolved in potable water at room temperature and drunk all at once. It is absorbed through the villi in the gastrointestinal tract and presented into the blood stream. It is progressively metabolized in the liver and then excreted renally.

Pharmacodynamics

Once in the blood, it is circulated to various tissues and organs. It never penetrates individual cells but remains within the circulatory system where it digests the envelope of a viral particle before the virus infects a new cell. This exposes the viral enzymes necessary for replication to an unusual environment (plasma) and thus they cannot function; moreover, exposing the viral genome to plasma leads to its metabolism in the usual biochemical fashion.

In Vitro Interaction of API with Some of the Common Drugs

Category	Generic/ Trade Name	Effect on API Potency	
		Inhibitory	None
Antibiotic/ Antimicrobial	Amoxicillin		✓
	Ampicillin		✓
	Ampiclox (Ampicillin and Cloxacillin)		✓
	Ciprofloxacin	✓	
	Metronidazole		✓
	Erythromycin		✓
	Fluconazole		✓
	Septrin		✓
	Acyclovir		✓
Antimalarial/ Antiparasitic	Fansida		✓

	Quinine	✓	
	Artemether-Lumefantrine		✓
	Albendazole		✓
Analgesic	Paracetamol		✓
	Paracetamol Caffeine Aspirin	✓	
	Diclofenac		✓
	Ibuprofen		✓
	Tramadol		✓
	Piroxicam		✓
Antihypertensive	Nifedipine		✓
	Losartan		✓
	Atenolol		✓
	Furosemide (Lasix)		✓
	Propranolol	✓	
Antidiabetic	Metformin		✓
	Glibenclamide		✓
Antiasthmatic	Aminophyline		✓
	Salbutamol		✓
	Prednisolone		✓
Anti-allergic	Cetirizine	✓	
	Cimetidine		✓
Antihyperlipidaemic	Atorvastatin		✓
Anticoagulant	Cardiac Aspirin		✓
Minerals	Magnesium/ Aluminium		✓
	Zinc	✓	
	Vitamin C		✓
	Vitamin B_1, B_2, B_6 and Niacinamide		✓

PROFILE OF HIV CURE CANDIDATE

Physicochemical Characteristics		
Dark Field Micrograph	Brand Name	$BertoV_1$
 X100	Nature of API	Polypeptide
	Minimum Anticipated Biological Effect Level	460 mg
	Infrared Spectroscopy	See pages 9 & 10
	Composition of Processed Drug (%)	• API 11.33% • Excipients 88.67%
	Kinase Activity	None
	Stability	Biological function lost beyond 43ºC
	Dissolution	100%
	Bioavailability	100%
	Dosage Form	Powder
	Route of Administration	Oral

Pharmacokinetics

The whole powder is dissolved in potable water at room temperature and drunk all at once. It is absorbed through the villi in the gastrointestinal tract and presented into the blood stream. It is progressively metabolized in the liver and then excreted renally.

Pharmacodynamics

Once in the blood, it is circulated to various tissues and organs. It never penetrates individual cells but remains within the circulatory system where it digests the envelope of a viral particle before the virus infects a new cell. This exposes the viral enzymes necessary for replication to an unusual environment (plasma) and thus they cannot function. Also, it digests the viral genome; moreover, exposing the viral genome to plasma leads to its metabolism in the usual biochemical fashion.

In Vitro Interaction of API with Some of the Common Drugs

Category	Generic/ Trade Name	Effect on API Potency	
		Inhibitory	None
Antibiotic/ Antimicrobial	Amoxicillin		✓
	Ampicillin		✓
	Ampiclox (Ampicillin and Cloxacillin)		✓
	Ciprofloxacin	✓	
	Metronidazole		✓
	Erythromycin		✓
	Fluconazole		✓
	Septrin		✓
	Acyclovir		✓
Antimalarial/ Antiparasitic	Fansida		✓

	Quinine	✓	
	Artemether-Lumefantrine		✓
	Albendazole		✓
Analgesic	Paracetamol		✓
	Paracetamol Caffeine Aspirin	✓	
	Diclofenac		✓
	Ibuprofen		✓
	Tramadol		✓
	Piroxicam		✓
Antihypertensive	Nifedipine		✓
	Losartan		✓
	Atenolol		✓
	Furosemide (Lasix)		✓
	Propranolol	✓	
Antidiabetic	Metformin		✓
	Glibenclamide		✓
Antiasthmatic	Aminophyline		✓
	Salbutamol		✓
	Prednisolone		✓
Anti-allergic	Cetirizine	✓	
	Cimetidine		✓
Antihyperlipidaemic	Atorvastatin		✓
Anticoagulant	Cardiac Aspirin		✓
Minerals	Magnesium/ Aluminium		✓
	Zinc	✓	
	Vitamin C		✓
	Vitamin B_1, B_2, B_6 and Niacinamide		✓

PROFILE OF HEPATITIS B CURE CANDIDATE

Physicochemical Characteristics		
Dark Field Micrograph	Brand Name	BertoHEP
 X100	Nature of API	Polypeptide
	Minimum Anticipated Biological Effect Level	460 mg
	Infrared Spectroscopy	See pages 9 & 10
	Composition of Processed Drug (%)	• API 11.33% • Excipients 88.67%
	Kinase Activity	None
	Stability	Biological function lost beyond 43^{o}C
	Dissolution	100%
	Bioavailability	100%
	Dosage Form	Powder
	Route of Administration	Oral

Pharmacokinetics

The whole powder is dissolved in potable water at room temperature and drunk all at once. It is absorbed through the villi in the gastrointestinal tract and presented into the blood stream. It is progressively metabolized in the liver and then excreted renally.

Pharmacodynamics

Once in the blood, it is circulated to various tissues and organs. It never penetrates individual cells but remains within the circulatory system where it digests the envelope of a viral particle before the virus infects a new cell. This exposes the viral enzymes necessary for replication to an unusual environment (plasma) and thus they cannot function. Also, it digests the viral genome; moreover, exposing the viral genome to plasma leads to its metabolism in the usual biochemical fashion.

In Vitro Interaction of API with Some of the Common Drugs

Category	Generic/ Trade Name	Effect on API Potency	
		Inhibitory	None
Antibiotic/ Antimicrobial	Amoxicillin		✓
	Ampicillin		✓
	Ampiclox (Ampicillin and Cloxacillin)		✓
	Ciprofloxacin	✓	
	Metronidazole		✓
	Erythromycin		✓
	Fluconazole		✓
	Septrin		✓
	Acyclovir		✓
Antimalarial/ Antiparasitic	Fansida		✓

	Quinine	✓	
	Artemether-Lumefantrine		✓
	Albendazole		✓
Analgesic	Paracetamol		✓
	Paracetamol Caffeine Aspirin	✓	
	Diclofenac		✓
	Ibuprofen		✓
	Tramadol		✓
	Piroxicam		✓
Antihypertensive	Nifedipine		✓
	Losartan		✓
	Atenolol		✓
	Furosemide (Lasix)		✓
	Propranolol	✓	
Antidiabetic	Metformin		✓
	Glibenclamide		✓
Antiasthmatic	Aminophyline		✓
	Salbutamol		✓
	Prednisolone		✓
Anti-allergic	Cetirizine	✓	
	Cimetidine		✓
Antihyperlipidaemic	Atorvastatin		✓
Anticoagulant	Cardiac Aspirin		✓
Minerals	Magnesium/ Aluminium		✓
	Zinc	✓	
	Vitamin C		✓
	Vitamin B_1, B_2, B_6 and Niacinamide		✓

PROFILE OF CANCER CURE CANDIDATE

Physicochemical Characteristics	
Brand Name	BertoCAN
Nature of API	Polypeptide
Minimum Anticipated Biological Effect Level	110 mg
Infrared Spectroscopy	See pages 9 & 10
Composition of Processed Drug (%)	• API 5.16% • Excipients 94.84%
Kinase Activity	None
Stability	Biological function lost beyond 43^{o}C
Dissolution	100%
Bioavailability	100%
Dosage Form	Powder
Route of Administration	Oral

Pharmacokinetics

The whole powder is dissolved in potable water at room temperature and drunk all at once. It is absorbed through the villi in the gastrointestinal tract and presented into the blood stream. It is progressively metabolized in the liver and then excreted renally.

Pharmacodynamics

Once in the blood, it is circulated to various tissues and organs. It never penetrates individual cells but remains within the circulatory system. It lyses cancerous cells, exposing their altered genetic material to normal biochemical pathways that eliminate them, which stops proliferation of cancerous cells.

In Vitro Interaction of API with Some of the Common Drugs

Category	Generic/ Trade Name	Effect on API Potency	
		Inhibitory	None
Antibiotic/ Antimicrobial	Amoxicillin		✓
	Ampicillin		✓
	Ampiclox (Ampicillin and Cloxacillin)		✓
	Ciprofloxacin	✓	
	Metronidazole		✓
	Erythromycin		✓
	Fluconazole		✓
	Septrin		✓
	Acyclovir		✓
Antimalarial/ Antiparasitic	Fansida		✓
	Quinine	✓	
	Artemether-Lumefantrine		✓
	Albendazole		✓
Analgesic	Paracetamol		✓
	Paracetamol Caffeine Aspirin	✓	
	Diclofenac		✓
	Ibuprofen		✓

	Tramadol		✓
	Piroxicam		✓
Antihypertensive	Nifedipine		✓
	Losartan		✓
	Atenolol		✓
	Furosemide (Lasix)		✓
	Propranolol	✓	
Antidiabetic	Metformin		✓
	Glibenclamide		✓
Antiasthmatic	Aminophyline		✓
	Salbutamol		✓
	Prednisolone		✓
Anti-allergic	Cetirizine	✓	
	Cimetidine		✓
Antihyperlipidaemic	Atorvastatin		✓
Anticoagulant	Cardiac Aspirin		✓
Minerals	Magnesium/ Aluminium		✓
	Zinc	✓	
	Vitamin C		✓
	Vitamin B_1, B_2, B_6 and Niacinamide		✓

18-Jul-21

4:11:02 PM



Comment;
BKG
HIV1/2
HEPATITIS B
CANCER
COVID-19

ANALYSED BY:

Robert Mijumbi

18/07/2021

CHECKED BY :

Ojuka Pius

18/07/2021.

06-Aug-21

5:20:31 PM



Comment;
BKG
HIV1/2
HEPATITIS B
CANCER
COVID-19

ANALYSED BY:

Robert Mgumia

06/08/2021

CHECKED BY :

Ojuka Pius

06/08/2021.